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Abstract
Although associated with unfavorable outcomes in the general population, abnormal blood levels
of various trace elements have not been consistently studied in the end-stage renal disease
population (with the notable exception of aluminum). This is surprising, as the uremic patient
treated by chronic dialysis loses one major route of trace element excretion and is exposed
systematically to a foreign environment (the dialysis fluid) possibly contaminated with significant
amounts of potential deleterious trace elements. Moreover, some biological important trace
elements may be lost through the dialysis membrane. Most studies to date demonstrated
significantly altered blood levels of trace elements in ESRD patients compared to healthy controls.
However, the biological impact of these abnormalities in renal disease is largely unknown and
should be clarified by future studies. A further step would be the design of well-controlled
randomized interventional studies, examining the potential therapeutic benefit of supplementing
one or more trace elements in ESRD patients, a population characterized by an impressive
mortality due to cardiovascular, infectious and neoplasic disease.
End-stage renal disease (ESRD) patients have a mortality
risk several times higher that their counterparts without
significant renal disease. This is due mainly to cardiovas-
cular (CV) disease, but is also caused by the enhanced risk
for infectious diseases and neoplasia [1]. Despite spectac-
ular improvements in chronic renal replacement therapies
(RRT), this excessive mortality remains particularly high
in dialysis patients, compared to the general population.
Extensive work has been done in the last decade on the
traditional and non-traditional CV risk factors in ESRD.
Research has been focused on the impact of "mineral"
(namely calcium and phosphate metabolism) abnormal-
ities and iron store derangements on morbidity and mor-
tality in ESRD patients [2,3]. This is not surprising, as this
work was largely driven by the industry, highly interested
in promoting drugs claimed to correct anemia or calcium-
phosphate metabolism abnormalities in a growing dialy-
sis population.
Although derangements in the metabolism of several trace
elements such as antimony, arsenic cadmium, molybde-
num, nickel, selenium and so on have been reported [4]
for several decades in patients with chronically (severely)
reduced renal function, such work – not sustained by
powerful companies and rather anecdotal, has been
largely ignored by the nephrological community. One
could speculate that the "trace" character of these ele-
ments discouraged more extensive research for psycholog-
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ical reasons. Trace elements are not (yet) routinely
determined in the blood of dialysis patients and many
uncertainties regarding these substances may trigger reluc-
tance in the mind of the practicing nephrologists.
Therefore, the systematic review and meta-analysis pub-
lished by Tonelli and co-workers this month in BMC Med-
icine  [5] may be of particular relevance. The authors
identified 128 – mostly European – eligible studies exam-
ining the whole blood, plasma, or serum levels of nine-
teen trace elements in chronic hemodialysis patients (HD
– the main modality of chronic RRT) in comparison to
healthy subjects. Overall, available literature suggests that
the blood levels of some trace elements such as cadmium,
chromium, fluorine, iodine, lead, or vanadium are high in
ESRD, whereas the levels of selenium, zinc or manganese
are lower in HD patients, compared to controls. The mag-
nitude of these differences was pronounced, suggesting
that renal patients could have subsequent different but
relevant (albeit in many cases asymptomatic) clinical
characteristics in this respect. Moreover, according to the
authors' investigation, the blood concentration of anti-
mony, iodine (!), tellurium, and thallium in renal failure
patients are a terra incognita for research until yet. The
authors conclude that, according to their review and meta-
analysis, the average blood levels for several (potentially)
biologically important trace elements are different in
hemodialysis patients compared to healthy control sub-
jects. This is not necessarily surprising, as more familiar
issues such as total cholesterol or blood pressure have a
peculiar significance in ESRD patients compared to the
general population; this phenomenon is generally charac-
terized as "inverse epidemiology" [6].
During the HD session, low-weight (and some middle
weight) molecules are removed driven by concentration
and pressure gradients through a semi-permeable mem-
brane. These processes are essential for the survival of
ESRD patients, as the dialysis process substitutes, far from
perfectly, for the excretory functions of the kidneys. How-
ever, in contrast to native kidneys, this depuration process
is non-discriminatory. As the authors highlight in their
article, hemodialysis may lead to a depletion of some bio-
logically essential substances, possibly already deficient
due to dietary restrictions. Moreover, trace substances
present in the dialysate may switch over to the blood and
accumulate in the patient, due to the lack of clearance by
the dialysis membrane and the (potential) remnant renal
function. This possibility was a harsh lesson for nephrol-
ogists more than two decades ago, when it became obvi-
ous that the (very efficient!) phosphate binder aluminum
hydroxide (as well as the contamination of the dialysate
water with aluminum) may lead to severe complications
such as aluminum dementia, severe anemia or adynamic
bone disease in HD patients [7].
Low levels of some essential trace elements have been
associated with adverse outcome in the general popula-
tion. For instance, zinc deficiency is linked to delayed
wound healing and decreased immunity leading to
increased infection susceptibility [8], frequently encoun-
tered in uremic patients. Moreover, excess concentrations
of cadmium and arsenic, as well as selenium deficiency,
have been associated with carcinogenicity in non-renal
populations [9]. Highly speculative (but pathophysiolog-
ically credible), reduced or enhanced blood levels of some
trace elements may be (even more) deleterious for the
chronic HD population.
The main merit of the discussed paper is that it offers the
first comprehensive and statistically very accurate review
and meta-analysis on trace elements blood levels in HD
patients compared to healthy controls. Of note however,
as the authors pointed out [5], matching for age and gen-
der was poor in the studies examined, eligibility status
and measurement error assessment were infrequent,
although technique was generally well-reported. Even a
mandatory issue such as the time spent on dialysis was
infrequently reported, although clearly significant for
depletion or accumulation of some trace elements. This is
not surprisingly, given the "Cinderella-status" of most of
these reports. Moreover, clinical studies in nephrology
and particularly in ESRD patients are generally under-
powered, far from the statistically accuracy of investiga-
tions in larger populations [10].
The key point is that the biological significance of either
accumulation or depletion of the studied trace elements
in the blood is largely unknown, at least in uremic
patients. Some data are available, on rather historical
grounds, on lead and arsenic accumulation [4,11]. The
scarcity of information is surprising, as the hemodialysis
patient is largely (and repeatedly) exposed to a "foreign"
medium which is the dialysate fluid. This water used for
dialysis is checked, according to current national and
international regulations, for some but not all relevant
trace elements. As mentioned, the measurement of blood
levels of trace elements is unusual in the clinical practice
of dialysis units, whereas the behavior of elements or mol-
ecules such as sodium, potassium, calcium, glucose or
bicarbonate are well-studied [12,13].
A serious limitation of the analyzed studies is that these
focus their investigation on the uremic blood. Moreover,
in some studies, whole blood concentrations of trace ele-
ments are investigated, whereas in others, just the serum
or the plasma levels of such elements are analyzed. How-
ever, the physiology of trace elements is far more compli-
cated, implying various routes of excretion, protein
binding and tissue concentrations [14]. Tissue concentra-
tions of trace elements may markedly differ from blood,Publish with BioMed Central    and   every 
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serum or plasma concentrations. Furthermore, the seques-
tration of trace elements is different from organ to organ,
as shown by studies investigating tissue deposition of alu-
minum or lanthanum [7,15].
The excellent review and meta-analysis of Tonelli et al [5]
is first of all a call for a more serious and systematic inves-
tigation of the role of trace elements disturbances in ure-
mic patients on hemodialysis. It is obvious that ESRD
have other characteristics in respect of trace elements than
the general population. Their correlates to infectious, car-
diovascular and neoplasic complications should be exten-
sively studied, as well as the potential interventions.
Given the actual therapeutic nihilism in renal patients [10]
this is not an easy task. However, well-controlled studies
on the clinical impact of trace elements blood and tissue
levels in ESRD are mandatory. In addition, intervention
studies using trace elements supplementation would be
even more helpful for the fate of the ESRD patient.
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